Although patients with IDH1 pathogenic variants have a significantly better prognosis than those with wild-type IDH1, these pathogenic variants are observed in only 4–7% of primary GBM patients, restricting their use as a biomarker4. This evidence concerns the gene IDH1 and glioblastoma.